Imaging approaches and radiomics: toward a new era of ultraprecision radioimmunotherapy?
暂无分享,去创建一个
Cyrus Chargari | R. Sun | E. Deutsch | A. Levy | S. Bockel | T. Henry | A. Carré | C. Robert | A. Laville | Anthony Hamaoui | I. Chaffai | É. Deutsch | A. Lévy
[1] Jianjiong Gao,et al. Multimodal integration of radiology, pathology and genomics for prediction of response to PD-(L)1 blockade in patients with non-small cell lung cancer , 2022, Nature Cancer.
[2] Jun Cheng,et al. Differentiation between immune checkpoint inhibitor‐related and radiation pneumonitis in lung cancer by CT radiomics and machine learning , 2022, Medical physics.
[3] N. Lennon,et al. Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial. , 2022, The Lancet. Oncology.
[4] A. Fedeli,et al. Exploring Response to Immunotherapy in Non-Small Cell Lung Cancer Using Delta-Radiomics , 2022, Cancers.
[5] I. C. Kok,et al. 89Zr-pembrolizumab imaging as a non-invasive approach to assess clinical response to PD-1 blockade in cancer. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.
[6] Adria Font Calvarons,et al. A Machine learning model trained on dual-energy CT radiomics significantly improves immunotherapy response prediction for patients with stage IV melanoma , 2021, Journal for ImmunoTherapy of Cancer.
[7] Zhiguo Zhou,et al. Immunotherapy treatment outcome prediction in metastatic melanoma through an automated multi-objective delta-radiomics model , 2021, Comput. Biol. Medicine.
[8] John O. Prior,et al. Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy , 2021, Cancer discovery.
[9] S. Welford,et al. Toward prediction of abscopal effect in radioimmunotherapy: Pre-clinical investigation , 2021, PloS one.
[10] A. Feng,et al. Radiomics Study for Predicting the Expression of PD-L1 and Tumor Mutation Burden in Non-Small Cell Lung Cancer Based on CT Images and Clinicopathological Features , 2021, Frontiers in Oncology.
[11] Xiu-juan Lei,et al. Association predictions of genomics, proteinomics, transcriptomics, microbiome, metabolomics, pathomics, radiomics, drug, symptoms, environment factor, and disease networks: A comprehensive approach , 2021, Medicinal research reviews.
[12] F. Mazzoni,et al. Preliminary Report on Computed Tomography Radiomics Features as Biomarkers to Immunotherapy Selection in Lung Adenocarcinoma Patients , 2021, Cancers.
[13] Mengchao Zhang,et al. Radiomics Analysis of Multi-Sequence MR Images For Predicting Microsatellite Instability Status Preoperatively in Rectal Cancer , 2021, Frontiers in Oncology.
[14] Yusheng Ye,et al. Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial. , 2021, The Lancet. Oncology.
[15] C. Zhou,et al. Combination of computed tomography imaging-based radiomics and clinicopathological characteristics for predicting the clinical benefits of immune checkpoint inhibitors in lung cancer , 2021, Respiratory Research.
[16] Ruijiang Li,et al. Radiographical assessment of tumour stroma and treatment outcomes using deep learning: a retrospective, multicohort study. , 2021, The Lancet. Digital health.
[17] L. Mainardi,et al. A CT-Based Radiomic Signature Can Be Prognostic for 10-Months Overall Survival in Metastatic Tumors Treated with Nivolumab: An Exploratory Study , 2021, Diagnostics.
[18] R. Gillies,et al. Hypoxia-Related Radiomics and Immunotherapy Response: A Multicohort Study of Non-Small Cell Lung Cancer , 2021, JNCI cancer spectrum.
[19] X. Ye,et al. Pre-Immunotherapy Contrast-Enhanced CT Texture-Based Classification: A Useful Approach to Non-Small Cell Lung Cancer Immunotherapy Efficacy Prediction , 2021, Frontiers in Oncology.
[20] A. Murphy,et al. Sequence of αPD-1 relative to local tumor irradiation determines the induction of abscopal antitumor immune responses , 2021, Science Immunology.
[21] J. Pearson,et al. Radiomics Biomarkers Correlate with CD8 Expression and Predict Immune Signatures in Melanoma Patients , 2021, Molecular Cancer Research.
[22] K. Harrington,et al. Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. , 2021, The Lancet. Oncology.
[23] S. Bakas,et al. Radiomics analysis for predicting pembrolizumab response in patients with advanced rare cancers , 2021, Journal for ImmunoTherapy of Cancer.
[24] M. Filetti,et al. CT based radiomic approach on first line pembrolizumab in lung cancer , 2021, Scientific Reports.
[25] A. Addeo,et al. Three-Dimensional Deep Noninvasive Radiomics for the Prediction of Disease Control in Patients With Metastatic Urothelial Carcinoma treated With Immunotherapy. , 2021, Clinical genitourinary cancer.
[26] Z. Ye,et al. Imaging Biomarkers to Predict and Evaluate the Effectiveness of Immunotherapy in Advanced Non-Small-Cell Lung Cancer , 2021, Frontiers in Oncology.
[27] H. Aerts,et al. Prognostic Value of Deep Learning-Mediated Treatment Monitoring in Lung Cancer Patients Receiving Immunotherapy , 2021, Frontiers in Oncology.
[28] QUAN LIU,et al. A CT-Based Radiomics Approach to Predict Nivolumab Response in Advanced Non-Small-Cell Lung Cancer , 2021, Frontiers in Oncology.
[29] Bingbing Ni,et al. A multi-omics-based serial deep learning approach to predict clinical outcomes of single-agent anti-PD-1/PD-L1 immunotherapy in advanced stage non-small-cell lung cancer. , 2021, American journal of translational research.
[30] R. Fietkau,et al. Prospective development and validation of a liquid immune profile-based signature (LIPS) to predict response of patients with recurrent/metastatic cancer to immune checkpoint inhibitors , 2021, Journal for ImmunoTherapy of Cancer.
[31] N. Obuchowski,et al. Incorporating radiomics into clinical trials: expert consensus endorsed by the European Society of Radiology on considerations for data-driven compared to biologically driven quantitative biomarkers , 2021, European Radiology.
[32] C. Porta,et al. A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLC , 2020, Cancer Immunology, Immunotherapy.
[33] A. Omuro,et al. Comparison of Radiomic Feature Aggregation Methods for Patients with Multiple Tumors , 2020, medRxiv.
[34] N. Paragios,et al. Radiomics to predict outcomes and abscopal response of patients with cancer treated with immunotherapy combined with radiotherapy using a validated signature of CD8 cells , 2020, Journal for ImmunoTherapy of Cancer.
[35] Joe Y. Chang,et al. Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials. , 2020, The Lancet. Respiratory medicine.
[36] Joe Y. Chang,et al. Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I/II trial , 2020, Journal for ImmunoTherapy of Cancer.
[37] A. Shinagare,et al. Predictive Role of Computed Tomography Texture Analysis in Patients with Metastatic Urothelial Cancer Treated with Programmed Death-1 and Programmed Death-ligand 1 Inhibitors. , 2020, European urology oncology.
[38] Jinming Yu,et al. Application and Prospects of Molecular Imaging in Immunotherapy , 2020, Cancer management and research.
[39] N. Lee,et al. Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell Carcinoma. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] Joe Y. Chang,et al. Use of Multi-Site Radiation Therapy as Systemic Therapy: A New Treatment Approach Personalized by Patient Immune Status. , 2020, International Journal of Radiation Oncology, Biology, Physics.
[41] R. Jeraj,et al. [18F]FDG PET Immunotherapy Radiomics Signature (iRADIOMICS) Predicts Response of Non-small-cell Lung Cancer Patients Treated with Pembrolizumab , 2020, Radiology and oncology.
[42] Nikos Paragios,et al. Standardization of brain MR images across machines and protocols: bridging the gap for MRI-based radiomics , 2020, Scientific Reports.
[43] Nikos Paragios,et al. Reinventing Radiation Therapy with Machine Learning and Imaging Bio-markers (Radiomics): state-of-the-art, challenges and perspectives. , 2020, Methods.
[44] K. Bensalah,et al. Radiomics can predict tumour response in patients treated with Nivolumab for a metastatic renal cell carcinoma: an artificial intelligence concept , 2020, World Journal of Urology.
[45] D. Dong,et al. Predicting response to immunotherapy in advanced non-small-cell lung cancer using tumor mutational burden radiomic biomarker , 2020, Journal for ImmunoTherapy of Cancer.
[46] K. Ghaghada,et al. Detection of response to tumor microenvironment–targeted cellular immunotherapy using nano-radiomics , 2020, Science Advances.
[47] M. Polley,et al. A Validated T Cell Radiomics Score is Associated with Clinical Outcomes Following Multi-site SBRT and Pembrolizumab. , 2020, International journal of radiation oncology, biology, physics.
[48] L. Schwartz,et al. Response Criteria for Intratumoral Immunotherapy in Solid Tumors: itRECIST , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[49] C. Faivre-Finn,et al. Radiomics as a personalized medicine tool in lung cancer: Separating the hope from the hype , 2020, Lung cancer.
[50] A. Benson,et al. Detection of Immunotherapeutic Response in a Transgenic Mouse Model of Pancreatic Ductal Adenocarcinoma Using Multiparametric MRI Radiomics: A Preliminary Investigation. , 2020, Academic radiology.
[51] Hongbing Lu,et al. Survival-relevant high-risk subregion identification for glioblastoma patients: the MRI-based multiple instance learning approach , 2020, European Radiology.
[52] Jeong Kon Kim,et al. Radiomics-based prediction model for outcomes of PD-1/PD-L1 immunotherapy in metastatic urothelial carcinoma , 2020, European Radiology.
[53] S. Novello,et al. 18F-FDG Pet Parameters and Radiomics Features Analysis in Advanced Nsclc Treated with Immunotherapy as Predictors of Therapy Response and Survival , 2020, Cancers.
[54] T. Nakano,et al. Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment , 2020, International Journal of Clinical Oncology.
[55] R. Steenbakkers,et al. The Image Biomarker Standardization Initiative: Standardized Quantitative Radiomics for High-Throughput Image-based Phenotyping. , 2020, Radiology.
[56] Jason M. Johnson,et al. Phase I study of intraventricular infusions of autologous ex-vivo-expanded NK cells in children with recurrent medulloblastoma and ependymoma. , 2020, Neuro-oncology.
[57] E. Deutsch,et al. Radiotherapy–immunotherapy combinations – perspectives and challenges , 2020, Molecular oncology.
[58] B. Taouli,et al. MRI radiomics features predict immuno-oncological characteristics of hepatocellular carcinoma , 2020, European Radiology.
[59] H. Lee,et al. Utility of CT radiomics for prediction of PD‐L1 expression in advanced lung adenocarcinomas , 2020, Thoracic cancer.
[60] Lisheng Wang,et al. Assessing PD-L1 Expression Level by Radiomic Features From PET/CT in Nonsmall Cell Lung Cancer Patients: An Initial Result. , 2020, Academic radiology.
[61] J. Galon,et al. Multiverse of immune microenvironment in metastatic colorectal cancer , 2020, Oncoimmunology.
[62] Kathryn J Fowler,et al. Assessing Radiology Research on Artificial Intelligence: A Brief Guide for Authors, Reviewers, and Readers-From the Radiology Editorial Board. , 2019, Radiology.
[63] C. H. Nielsen,et al. Quantitative PET imaging of PD-L1 expression in xenograft and syngeneic tumour models using a site-specifically labelled PD-L1 antibody , 2019, European Journal of Nuclear Medicine and Molecular Imaging.
[64] R. Gillies,et al. Radiomics of 18F-FDG PET/CT images predicts clinical benefit of advanced NSCLC patients to checkpoint blockade immunotherapy , 2019, European Journal of Nuclear Medicine and Molecular Imaging.
[65] Aaron Carass,et al. DeepHarmony: A deep learning approach to contrast harmonization across scanner changes. , 2019, Magnetic resonance imaging.
[66] Sinae Kim,et al. Impact of Treatment-Related Lymphopenia on Immunotherapy for Advanced Non-Small Cell Lung Cancer. , 2019, International journal of radiation oncology, biology, physics.
[67] Xiaoli Tang,et al. The role of artificial intelligence in medical imaging research , 2019, BJR open.
[68] A. Madabhushi,et al. Changes in CT Radiomic Features Associated with Lymphocyte Distribution Predict Overall Survival and Response to Immunotherapy in Non–Small Cell Lung Cancer , 2019, Cancer Immunology Research.
[69] Amber L. Simpson,et al. Radiomics-based prediction of microsatellite instability in colorectal cancer at initial computed tomography evaluation , 2019, Abdominal Radiology.
[70] J. Aerts,et al. Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial. , 2019, JAMA oncology.
[71] G. Coukos,et al. Rational combinations of immunotherapy with radiotherapy in ovarian cancer. , 2019, The Lancet. Oncology.
[72] Eric Deutsch,et al. Optimising efficacy and reducing toxicity of anticancer radioimmunotherapy. , 2019, The Lancet. Oncology.
[73] E. Goetghebeur,et al. Randomized Phase 1 Trial of Pembrolizumab with Sequential Versus Concomitant Stereotactic Body Radiotherapy in Metastatic Urothelial Carcinoma. , 2019, European urology.
[74] Emily B. Ehlerding,et al. Noninvasive Imaging and Quantification of Radiotherapy-Induced PD-L1 Upregulation with 89Zr-Df-Atezolizumab. , 2019, Bioconjugate chemistry.
[75] H. Aerts,et al. Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[76] R. Gillies,et al. Novel clinical and radiomic predictors of rapid disease progression phenotypes among lung cancer patients treated with immunotherapy: An early report. , 2019, Lung cancer.
[77] V. Servois,et al. Novel patterns of response under immunotherapy , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[78] Fanny Orlhac,et al. Validation of A Method to Compensate Multicenter Effects Affecting CT Radiomics. , 2019, Radiology.
[79] D. Gu,et al. Pretreatment prediction of immunoscore in hepatocellular cancer: a radiomics-based clinical model based on Gd-EOB-DTPA-enhanced MRI imaging , 2019, European Radiology.
[80] Benjamin Haibe-Kains,et al. Vulnerabilities of radiomic signature development: The need for safeguards. , 2019, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[81] A. Debucquoy,et al. The Link between the Multiverse of Immune Microenvironments in Metastases and the Survival of Colorectal Cancer Patients. , 2018, Cancer cell.
[82] Joe Y. Chang,et al. Time to abandon single-site irradiation for inducing abscopal effects , 2018, Nature Reviews Clinical Oncology.
[83] Irène Buvat,et al. Radiomics in Nuclear Medicine Applied to Radiation Therapy: Methods, Pitfalls, and Challenges. , 2018, International journal of radiation oncology, biology, physics.
[84] D. Planchard,et al. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC , 2018, The New England journal of medicine.
[85] N. Paragios,et al. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study. , 2018, The Lancet. Oncology.
[86] Josien P. W. Pluim,et al. Not‐so‐supervised: A survey of semi‐supervised, multi‐instance, and transfer learning in medical image analysis , 2018, Medical Image Anal..
[87] Steven J. M. Jones,et al. The Immune Landscape of Cancer , 2018, Immunity.
[88] R. Fietkau,et al. Immune modulatory effects of radiotherapy as basis for well-reasoned radioimmunotherapies , 2018, Strahlentherapie und Onkologie.
[89] Manish R. Sharma,et al. Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[90] J. Wolchok,et al. Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[91] R. Fietkau,et al. Immunomodulation by ionizing radiation—impact for design of radio‐immunotherapies and for treatment of inflammatory diseases , 2017, Immunological reviews.
[92] Andriy Fedorov,et al. Computational Radiomics System to Decode the Radiographic Phenotype. , 2017, Cancer research.
[93] P. Lambin,et al. Radiomics: the bridge between medical imaging and personalized medicine , 2017, Nature Reviews Clinical Oncology.
[94] J. Melotek,et al. The ADscopal Effect? Control of Partially Irradiated Versus Completely Irradiated Tumors on a Prospective Trial of Pembrolizumab and SBRT Per NRG-BR001 , 2017 .
[95] Eric Deutsch,et al. [Computational medical imaging (radiomics) and potential for immuno-oncology]. , 2017, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.
[96] P. Lambin,et al. Defining the biological basis of radiomic phenotypes in lung cancer , 2017, eLife.
[97] C. N. Coleman,et al. DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity , 2017, Nature Communications.
[98] N. Paragios,et al. Promises and challenges for the implementation of computational medical imaging (radiomics) in oncology , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[99] R. Ferris,et al. Preclinical immunoPET/CT imaging using Zr-89-labeled anti-PD-L1 monoclonal antibody for assessing radiation-induced PD-L1 upregulation in head and neck cancer and melanoma , 2017, Oncoimmunology.
[100] F. Mornex,et al. [Immunotherapy and radiotherapy]. , 2017, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.
[101] Ragini Verma,et al. Harmonization of multi-site diffusion tensor imaging data , 2017, NeuroImage.
[102] Robert Ford,et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. , 2017, The Lancet. Oncology.
[103] Ralph R. Weichselbaum,et al. Radiotherapy and immunotherapy: a beneficial liaison? , 2017, Nature Reviews Clinical Oncology.
[104] Guy Cazuguel,et al. Multiple-Instance Learning for Medical Image and Video Analysis , 2017, IEEE Reviews in Biomedical Engineering.
[105] Charles Ferté,et al. Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1 , 2016, Clinical Cancer Research.
[106] J. Wolchok,et al. Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[107] Eric Deutsch,et al. In Regard to Mattonen et al. , 2016, International journal of radiation oncology, biology, physics.
[108] T. Schmid,et al. Local Tumor Treatment in Combination with Systemic Ipilimumab Immunotherapy Prolongs Overall Survival in Patients with Advanced Malignant Melanoma , 2016, Cancer Immunology Research.
[109] H. Aerts,et al. Applications and limitations of radiomics , 2016, Physics in medicine and biology.
[110] Erich P Huang,et al. RECIST 1.1-Update and clarification: From the RECIST committee. , 2016, European journal of cancer.
[111] M. Bartholomä,et al. High-Resolution PET Imaging with Therapeutic Antibody-based PD-1/PD-L1 Checkpoint Tracers , 2016, Theranostics.
[112] Miao-Fen Chen,et al. The role of PD-L1 in the radiation response and prognosis for esophageal squamous cell carcinoma related to IL-6 and T-cell immunosuppression , 2016, Oncotarget.
[113] I. Weissman,et al. Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging , 2015, Proceedings of the National Academy of Sciences.
[114] S. Gambhir,et al. Novel Radiotracer for ImmunoPET Imaging of PD-1 Checkpoint Expression on Tumor Infiltrating Lymphocytes. , 2015, Bioconjugate chemistry.
[115] Marion Smits,et al. Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials. , 2015, Neuro-oncology.
[116] S. Demaria,et al. Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial. , 2015, The Lancet. Oncology.
[117] Joe Y. Chang,et al. The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant. , 2015, Cancer treatment reviews.
[118] H. Kohrt,et al. Ablative Tumor Radiation Can Change the Tumor Immune Cell Microenvironment to Induce Durable Complete Remissions , 2015, Clinical Cancer Research.
[119] H. Ishwaran,et al. Radiation and Dual Checkpoint Blockade Activates Non-Redundant Immune Mechanisms in Cancer , 2015, Nature.
[120] N. Agarwal,et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. , 2014, The Lancet. Oncology.
[121] F. Marincola,et al. Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours , 2013, The Journal of pathology.
[122] S. Demaria,et al. Combining radiotherapy and cancer immunotherapy: a paradigm shift. , 2013, Journal of the National Cancer Institute.
[123] R. Johnstone,et al. Radiotherapy increases the permissiveness of established mammary tumors to rejection by immunomodulatory antibodies. , 2012, Cancer research.
[124] P. A. Futreal,et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. , 2012, The New England journal of medicine.
[125] R. Gillies,et al. The biology underlying molecular imaging in oncology: from genome to anatome and back again. , 2010, Clinical radiology.
[126] Axel Hoos,et al. Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria , 2009, Clinical Cancer Research.
[127] N. Kawashima,et al. Fractionated but Not Single-Dose Radiotherapy Induces an Immune-Mediated Abscopal Effect when Combined with Anti–CTLA-4 Antibody , 2009, Clinical Cancer Research.
[128] R. Weichselbaum,et al. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. , 2009, Blood.
[129] S. Demaria,et al. Systemic effects of local radiotherapy. , 2009, The Lancet. Oncology.
[130] N. Kawashima,et al. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. , 2004, International journal of radiation oncology, biology, physics.
[131] Wendy Brown,et al. Variability in response assessment in solid tumors: effect of number of lesions chosen for measurement. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[132] Yoshua Bengio,et al. Convolutional networks for images, speech, and time series , 1998 .
[133] G. Kalemkerian,et al. Small cell lung cancer , 2010, Seminars in Respiratory and Critical Care Medicine.
[134] A. Ribas,et al. An Effective Immuno-PET Imaging Method to Monitor CD8-Dependent Responses to Immunotherapy. , 2016, Cancer research.
[135] Heather Zeiger,et al. An Update on Genetic Testing: Separating the Hope from the Hype , 2012 .
[136] L. Schwartz,et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.
[137] John Adams. Assessing , 2020, Transport Planning.
[138] R. Mole. Whole body irradiation; radiobiology or medicine? , 1953, The British journal of radiology.